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ABSTRACT 
 
OBJECTIVE 
 The recent increase of pertussis cases worldwide has generated questions 
regarding the utility of extracorporeal membrane oxygenation (ECMO) for children with 
pertussis. We aimed to evaluate factors associated with ECMO outcome. 
 
DESIGN 
 The study was designed in two parts: a retrospective analysis of the 
Extracorporeal Life Support Organization Registry to identify factors independently 
linked to outcome, and an expanded dataset from individual institutions to examine the 
association of white blood cell count, pulmonary hypertension and leukodepletion with 
survival.  
 
SETTING 
 ELSO Registry database from 2002 though 2015, and contributions from 19 
international centers 
 
PATIENTS 
 200 infants from the ELSO Registry and expanded data on 73 children 
 
INTERVENTIONS 
 None 
 
MEASUREMENTS AND MAIN RESULTS 
 Of the 200 infants who received ECMO for pertussis, only 56 survived (28%).  In 
a multivariable logistic regression analysis, the following variables were independently 
associated with increased chance of survival: older age (OR 1.43 [1.03, 1.98] p=0.034), 
higher PaO2/FiO2 ratio (OR 1.10 [1.03, 1.17] p=0.003) and longer intubation time prior to 
the initiation of ECMO (OR 2.10 [1.37, 3.22] p=0.001).  The use of vasoactive 
medications (OR 0.33 [0.11, 0.99] p=0.047), and renal neurological or infectious 
complications (OR 0.21 [0.08, 0.56] p=0.002) were associated with increased mortality. 
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 In the expanded dataset (n =73), leukodepletion was independently associated 
with increased chance of survival (OR 3.36 [1.13, 11.68] p=0.03) while the presence of 
pulmonary hypertension was adverse (OR 0.06 [0.01, 0.55] p=0.01).  
 
CONCLUSIONS 
 The survival rate for infants with pertussis who received ECMO support remains 
poor. Younger age, lower PaO2/FiO2 ratio, vasoactive use, pulmonary hypertension and 
a rapidly progressive course were associated with increased mortality. Our results 
suggest pre-ECMO leukodepletion may provide a survival advantage.  
 
 
KEY WORDS 
Extracorporeal membrane oxygenation, pertussis, leukodepletion, pulmonary 
hypertension, infants, Extracorporeal life support organization. 
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Introduction 
 
 Pertussis is a highly contagious respiratory illness caused by the Gram-negative 
bacterium Bordetella pertussis. Severe disease occurs predominantly in infancy and can 
include respiratory failure/apnea, pulmonary hypertension and neurologic complications. 
Estimates from the World Health Organization in 2008 suggested that 16 million cases of 
pertussis occurred worldwide and 195,000 children died from this vaccine-preventable 
disease [1]. In 2012, the Centers for Disease Control reported over 48,000 pertussis 
cases in the United States, the most since 1955. [2]. Due to waning acellular pertussis 
vaccine immunity, epidemics are expected to continue [3].  
 
 Extracorporeal membrane oxygenation (ECMO) has been used in children with 
respiratory failure for over 40 years. Since 2002, a resurgence of pertussis cases 
worldwide has correlated with increased utilization of ECMO for this disease [4]. Many 
have questioned the utility of ECMO in pertussis patients, citing concerns about low 
survival rates and a potentially irreversible process once pulmonary hypertension 
develops. Prior reports from the Extracorporeal Life Support Organization (ELSO) 
Registry demonstrated survival rates of 30% for pertussis patients receiving ECMO 
support [5, 6], which is significantly lower than most other ECMO respiratory indications.  
 
 Factors associated with increased mortality include younger age, elevated white 
blood cell (WBC) count and pulmonary hypertension (PHTN) [7, 8]. Following 
encouraging single institution reports, leukodepletion via exchange transfusion or 
leukofiltration has been introduced as a management strategy to attenuate the disease 
severity of critical pertussis patients with hyperleukocytosis, [6, 9-14].  
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 The aim of this study was to determine the predictors of survival in pertussis 
patients placed onto ECMO in the current era. As part of this investigation, we also 
sought to explore the impact of highest white blood cell (WBC) count, presence of PHTN 
and use of leukodepletion (LD) techniques prior to ECMO initiation. We hypothesized the 
presence of PHTN and an elevated WBC count would decrease the chances of survival 
and that LD would improve the chance of survival for children with pertussis who 
received ECMO support.  
 
Materials and Methods 
 
Data Collection and Study Population: 
 
 The study was designed in two parts. The first was an analysis of the ELSO 
Registry database (Ann Arbor, Michigan) to identify factors independently associated 
with outcome [4]. The registry contains data from over 35,000 neonates and children 
with respiratory failure from > 300 centers worldwide. The second was a non-ELSO 
expanded dataset to test the hypothesis regarding the relationship between WBC count, 
PHTN, LD and survival. Survival to hospital discharge was defined as the primary 
outcome. The additional de-identified data from 19 contributing centers, obtained their 
own institutional permission if required. Children’s Hospital of Orange County granted 
IRB exemption.  
 
 A retrospective review of the ELSO database was performed for all patients with 
a primary or secondary diagnosis of pertussis between January 1, 2002 and January 1, 
2015. The specific time period was selected due to a previous ELSO report [5], and 
because leukocyte reduction for pertussis was increasingly adopted after a publication in 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
the year 2000 suggesting exchange transfusion [15]. To isolate patients most vulnerable 
to pertussis, we excluded patients over 1 year of age. Patients who required more than 
one ECMO course were excluded, as it was unclear if the impetus for a repeat course 
was related to pertussis or a subsequent complication.  
 
 Data examined included the following: patient demographic details, diagnoses, 
duration of ECMO, mode of ECMO, survival to hospital discharge or transfer, and time to 
death or transfer. Pre-ECMO variables included: ventilator days, calculated oxygenation 
index (OI), serum pH, positive end expiratory pressure (PEEP), PaO2/FiO2 (P/F) ratio, 
PaCO2, inotrope infusion requirement, cardiac arrest, use of high frequency ventilation 
(HFOV), inhaled nitric oxide (iNO) administration and pre-ECMO co-infection.  
 
 A complete organ assessment prior to ECMO initiation can be difficult in the 
setting of rapid disease progression. Therefore, we considered neurologic complications 
and renal complications during ECMO as risk factors, recognizing these may in part be 
caused by pertussis and may be present before ECMO commencement. Neurologic and 
renal complications were based on defined ELSO Registry fields as follows: the 
presence of seizures, intracranial bleed or stroke while on ECMO support, and the use 
of renal support (such as hemodialysis or hemofiltration). A further risk factor considered 
was infection acquired during ECMO support.  
 
 Since hyperleukocytosis and the PHTN are not captured in the ELSO database, 
the investigators contacted ELSO-contributing pediatric centers to retrospectively obtain 
these data. The 19 centers were selected based on personal communication from one or 
more of the investigators and their willingness to submit data from every patient placed 
onto ECMO with pertussis between 2002 through 2015. Additional information sought 
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included highest WBC count at any time from intensive care unit (ICU) admission until 
ECMO commencement, the use of LD techniques at any time from ICU admission until 
ECMO commencement, and evidence of PHTN or right ventricular (RV) failure at any 
time from ICU admission throughout the course of ECMO.  
 
 Use of LD techniques was defined as exchange transfusion, leukopheresis, 
plasmapheresis or leukofiltration. Evidence of RV failure or PHTN (right ventricle 
pressure > 50% systemic) was defined by set echocardiographic parameters including 
but not limited to: tricuspid regurgitation pressure estimate, flattened septum and/or right 
ventricular systolic dysfunction.  
 
Statistical Analysis 
Variables are presented as number with percentage, mean with standard deviation (SD) 
or median and inter quartile range (IQR) for skewed data.  
 
Part 1: ELSO Registry analysis 
 
 Univariate logistic regression analysis was undertaken to examine the 
association of each of the following pre-ECMO factors: age, pH, P/F ratio, OI, pre-ECMO 
ventilation days, inotrope use, cardiac arrest, co-infection, iNO usage, and year of 
ECMO on survival to hospital discharge. Due to large numbers of missing data for PEEP 
and PaCO2, these factors were not included in the univariate analysis. Similarly 
examined variables while receiving ECMO support included mode of ECMO, co-
infection, and neurologic or renal complications.  
 
 Although ECMO duration was not included in the regression analyses, a 
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 8 
descriptive analysis of the relationship between ECMO duration and survival was 
undertaken using fractional polynomials.  
 
 All factors were selected a priori and those found to be significant (p<0.05) on 
univariate analysis were assessed further in multivariable analyses. In the multiple 
variable models P/F ratio was considered instead of OI due to larger numbers of missing 
values for OI. A multiple logistic regression model was constructed including all variables 
meeting the preset criteria (Multiple Model I) and second a multiple logistic regression 
model was constructed including only variables definitively known prior to commencing 
ECMO (Multiple Model II).  
 
 The goodness of fit of the final models was assessed using the Hosmer-
Lemeshow test. The c statistic or area under the receiver operator curve (AUC) was 
used to assess model discrimination. Results are presented as odds ratios (OR) for 
survival to hospital discharge, with 95% confidence intervals (CI) and p values.  
 
Part 2: Expanded dataset  
 
 Data was acquired from 19 centers worldwide (see acknowledgements), 
including demographic information, survival, highest pre-ECMO WBC count, use of LD 
techniques, and evidence of PHTN or RV failure. Univariate logistic regression was used 
to assess the the relationship between survival rate and each of these factors in turn. A 
multiple logistic regression model was generated to evaluate which factors were 
independently linked to outcome.  
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 A value of p < 0.05 was deemed significant. Analysis was performed using the 
statistics package Stata (Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP). 
 
Results 
 
Part 1: ELSO Registry analysis 
 
 A search of the entire ELSO database (1989-2015) revealed a total of 275 
patients placed on ECMO for pertussis with a survival rate of 80/275 (29%), this included 
adults, children and neonates. For completeness of information we listed all pertussis 
patients from the ELSO database in Table 1 along with the number and proportion of 
survivors. Patients were excluded from further analysis if they did not meet inclusion 
criteria. A total of 200 infants formed the study group. There was no increase in survival 
from 2002-2015 (p= 0.43). The study group survival rate was 56/200 (28%) with a 
median (IQR) age of 39 [27 – 59] days and a median (IQR) duration of 13 [5, 26] days 
on ECMO support (Table 2).  
 
 The most frequent pre-ECMO intervention was inotrope use, utilized in 176/200 
(88%) of patients. Additional therapy included iNO in 154/200 (77%). Pre-ECMO co-
infection occurred in 44/200 (22%) of patients and 36/200 (18%) suffered a cardiac 
arrest preceding ECMO. Five infants were classified as ECPR and all 5 died. VA ECMO 
support was initiated in 164/200 (82%) of patients.  
 
 High rates of renal, neurologic and infectious complications were reported. Renal 
complications were reported in 154/200 (77 %) and neurologic complications in 80/200 
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(40%) of patients. In addition, 56/200 (28%) were noted to have a co-infection while 
receiving ECMO. 
 
 Univariate analysis of factors associated with survival is shown in Table 2, with 
variable results presented separately for survivors and non-survivors. Older age (OR 
1.65 [1.17, 2.32] p=0.004), higher pH (OR 1.29 [1.05, 1.59] p=0.015), increased P/F ratio 
(OR 1.06 [1.007, 1.12] p=0.03) and a longer intubation time prior to ECMO cannulation 
(log transformed because of skewed distribution, OR, 2.20 [1.40, 3.45] p= 0.001) were 
significantly associated with improved survival when each was considered in isolation. 
There was no difference in survival between VV and VA ECMO modes (OR 1.92 [0.63, 
5.83] p=0.25). Inotrope use (OR 0.30 [0.13, 0.71] p= 0.006), higher OI (OR 0.78 [0.65, 
0.93] p = 0.006) and one or more complication (infection, renal or neurologic) while on 
ECMO (OR 0.27 [0.12, 0.60] p=0.001) were significantly associated with a reduced 
chance of survival. 
 
 The primary multivariable logistic regression analysis (Multiple Model I) identified 
the following variables as independently and significantly associated with the chance of 
survival: increased age (OR 1.43 [1.03, 1.98] p=0.034), increased P/F ratio (OR 1.10 
[1.03, 1.17] p=0.003), and increased intubation time prior to the initiation of ECMO (OR 
2.10 [1.37, 3.22] p=0.001) were all protective.  The use of vasoactive medication (OR 
0.33 [0.11, 0.99] p=0.047), and any complication on ECMO (infection, renal or 
neurologic) was adverse (OR 0.21 [0.08, 0.56] p=0.002) (Table 3). The c statistic was 
0.80, displayed as AUC (Figure 1), with Hosmer-Lemeshow p=0.52. The secondary 
multivariable model (Multiple Model II) consisting of pre-ECMO variables only (Table 3) 
contained the same risk factors with the exception of the “on-ECMO” complications and 
had a c statistic of 0.78 with Hosmer-Lemeshow p=0.55. 
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 The duration of ECMO support as it relates to chance of survival in pertussis 
patients is depicted in Figure 2. Survival was at an optimum with an ECMO duration of 
15 days and starts to decline thereafter.  
 
Part 2: Expanded dataset 
 
 Expanded data was collected on 74 children from 19 international centers and is 
shown in Table 4. One teenager was excluded as to remain consistent with the study 
population defined above. The overall survival in this selected group was 23/73 (32%). 
The mean (SD) WBC was 78,000 (35,000) white blood cells per microliter in survivors 
and 77,000 (26,000) white blood cells per microliter in those who died. Pre-ECMO LD 
was used in 9 of 23 survivors and in 9 of 50 non-survivors. The survival rate amongst 
leukodepleted infants was 9/18 (50%), whilst the survival rate was only 14/55 (25%) in 
the non-leukodelpeted. PHTN was present in 18/23 (78%) survivors and in 49 of 50 
(98%) non-survivors.  
            In univariate analyses, WBC count did not relate to survival (OR 1.01 [0.85, 1.20] 
p=0.88), nor did age (neonatal versus infant age group) (OR 2.45 [0.72, 8.34] p=0.15). 
The presence of PHTN or RV failure (n=67) was associated with a reduced chance of 
survival (OR 0.07 [0.01, 0.67] p=0.02). Only 18 of 73 patients received LD, and in the 
univariate analysis, there was no statistically significant association with increased 
survival (OR 2.93 [0.97, 8.84] p=0.06).  
 
 In a multiple analysis, both LD and PHTN were independently associated with 
outcome. Those patents with evidence of PHTN or RV failure had a decreased chance 
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of survival (OR 0.06 [0.01, 0.55] p=0.01). Children who received LD had an increased 
chance of survival (OR 3.36 [1.13, 11.68] p=0.03).  
 
Discussion  
 
 Based on ELSO Registry data, the overall survival rate for infants with critical 
pertussis who received ECMO support remains low and has not improved over the past 
decade. We present analysis of risk factors for survival outcome with the aim of assisting 
in clinical decision making, both from the perspective of the entire course of critical 
pertussis (Multiple Model I) and from the perspective of clinical features definitively 
known prior to ECMO (Multiple Model II).  
 
 Many studies have demonstrated that pertussis in younger age groups 
(particularly those < 2 months) is associated with severe disease and higher mortality [7, 
16- 20]. Consistent with those previous studies, we observed a decreased chance of 
survival in younger infants with pertussis. In 2011, Zabrocki et al. reviewed the ELSO 
Respiratory database from 1993 to 2007 [21]. They reported a survival of 38% for 
pertussis patients (n=85) as compared to 28% in our cohort (n=200). Since that time, the 
number of centers contributing to ELSO has doubled, and our study isolated children 
most vulnerable to pertussis, those less than 1-year of age. 
 
 A longer duration of mechanical ventilation (up to 13 days) was associated with 
increased survival, perhaps due to a less fulminant disease process. Pertussis patients 
who had a rapidly progressive course (time from intubation to ECMO) had a decreased 
chance of survival. Other studies have suggested a rapidly progressive course with 
pertussis is associated with higher mortality [17, 20, 22-24] with many patients requiring 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 13 
intubation within 24 hours of hospital arrival and either ECMO support or death within 2 
days.  
  
 Infectious, neurologic and renal complications while on ECMO support were 
much higher in our pertussis study group than what is currently reported for respiratory 
ECMO cases [4], and this suggests that underlying pertussis disease was a contributor 
to these complications. The co-infection rate during ECMO was 28% in our study 
population (organisms included streptococcus, staphylococcus, gram negative bacteria, 
respiratory viruses and yeast) whereas the ELSO registry reports infectious 
complications at 5.8% (neonatal respiratory database) and 17% (pediatric respiratory 
database) [4]. The increased co-infection rate may be a reflection of the longer duration 
of ECMO, however this was not explored further and is a limitation of the study. 
Neurologic complications and the use of renal replacement therapy are known hazards 
of ECMO [25] but are also frequently described in patients with pertussis who did not 
receive ECMO support [7,8,17, 26-28]. It is not possible to discern whether the high 
neurologic and renal complication rates in this study (3 to 5 times higher than the ELSO 
Registry data) are a result of ECMO or the underlying disease. Since both neurologic 
and renal complications can result from ECMO therapy and can occur as an indicator of 
multi-organ involvement with pertussis, every effort should be made to assess other 
organs prior to ECMO initiation.  
 
 PHTN has been linked to worse outcome in pertussis [5, 7, 8, 15, 17]. Many 
authorities believe that once a pertussis patient develops PHTN, it becomes irreversible 
[7, 19, 29], possibly due to leukocyte vascular plugging, veno-occlusive disease, and/or 
lung necrosis, [5, 19, 23, 24, 27, 30]. While the exact mechanism is unknown, pertussis 
toxin-mediated hyperinflammation and leukocyte activation has been shown to be 
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involved [19]. Only a handful of case reports have described patients with pertussis and 
PHTN surviving after ECMO [31-34]. We report that pulmonary hypertension was 
significantly and independently related to mortality; however, the majority of the patients 
in our study (69 of 73) had PHTN or RV failure.  
 
 Recently, several authors have questioned whether exchange transfusion or 
other leukoreduction techniques can improve outcome. Romano and colleagues 
published the first report of an infant with pertussis and suprasystemic PHTN who 
survived without ECMO, but with a double volume exchange transfusion [10]. Over the 
past decade, investigators at Great Ormond Street Hospital adopted an aggressive LD 
strategy for children with pertussis. They observed significantly better outcomes than 
predicted for the patients who received LD [6]. Our results of additional data collected 
from 19 international centers indicate that LD techniques prior to ECMO commencement 
increased survival rates (50%, 9 of 18). We did not explore leukoreduction while on the 
ECMO circuit (such as using a leukofilter) but this approach may also improve survival 
[6,12,33]. Our study did not evaluate which type of LD method was preferred (exchange 
transfusion versus leukopheresis).  
 
 When ECMO is used for pertussis the average duration is relatively long and 
resource utilization is high, inflicting a heavy financial burden worldwide. An infant with 
pertussis in Oregon who required 43 days of ECMO support and a 90-day hospital stay 
totaled $1.5 million dollars. [34] The Australia and New Zealand Paediatric Intensive 
Care group (ANZPIC) also report a heavy financial burden of over $1 million per year in 
direct pertussis-related hospitalization costs [20].  
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 One of the most difficult tasks for an intensive care clinician is to determine if 
ECMO provides a survival advantage. A rapidly deteriorating young infant with pertussis-
induced PHTN and multi organ involvement has a low chance of survival even with 
ECMO support. A decision to offer ECMO in such cases should take into consideration 
local protocols and the circumstances of each individual case.  
 
Limitations  
This was a retrospective database review with the limitations inherent in databases. The 
ELSO registry is a voluntary database and there is no standardized quality measurement 
for the accuracy of data reported. There is no verification process to confirm a 
polymerase chain reaction or culture proven diagnosis of pertussis. Although there are 
various types of neurologic and renal complications, we were limited to the complication 
categories reported in the ELSO database.  Despite basing the study on the ELSO 
Registry and multiple center involvement, the findings are limited by their retrospective 
nature, non-randomization and small numbers, particularly in the area of leukoreduction 
(n=18). 
 
Pertussis patients who present with pneumonia (as compared to those presenting with 
apnea) may have worse outcomes [18, 26]. Unfortunately, we cannot address mortality 
related to symptoms at presentation because this data is not routinely available in the 
ELSO registry. We are unable to report on the long-term outcome of these patients 
particularly regarding neurodevelopmental sequelae, as this data was not available.  
 
Conclusion 
 The survival rate for children with pertussis who received ECMO support remains 
poor (28%). Younger age, lower PaO2/FiO2 ratio, vasoactive use, pulmonary 
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hypertension and a rapidly progressive course were independently and significantly 
associated with increased mortality. However, pre-ECMO leukodepletion techniques 
may provide a survival advantage. 
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Figure 1: ROC for Multivariable Risk Model I for Survival of Pertussis Patients on 
ECMO 
 
PLACE FIGURE HERE 
 
Area under the Receiver Operator Curve (ROC) = 0.81 
 
 
 
 
 
 
 
Figure 2: Probability of Survival Related to Duration of ECMO in Pertussis patients 
 
PLACE FIGURE HERE  
 
Vertical lines are at 5, 15 and 35 days  
Footnote: Missing data for 6 patients 
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 Table 1: Defining the Study Group 
 
Categories Number Proportion of survivors 
All Pertussis in database        275 80/275 (29%) 
Adults in database* 7 2/7 (28%) 
Neonate and Pediatric prior to 2002* 60 18/60 (30%) 
Multiple runs* 6 3/6 (50%) 
Children > 1 year of age* 2 2/4 (50%) 
   
Neonate and Pediatric Final Study Group 200 56/200 (28%) 
* Removed from final analysis  
 
Table 1
Table 2: Risk factors of interest and their relationship with survival in pertussis patients on ECMO: Univariate Analysis 
 
Pre-ECMO Parameter Number with missing data 
Survivors: non-survivors 
Mean (SD), or number (%) 
for survivors 
n = 56 
Mean (SD), or number (%) 
for non-survivors 
n = 144 
OR (95% CI) P value 
Age (per month)  1.9 (1.2) 1.4 (0.9) 1.65 (1.17, 2.32) 0.004 
pH (per 0.1 units) 2 : 7 71.8 (1.2) 71.2 (1.7) 1.29 (1.05, 1.59) 0.015 
P/F ratio (per 10-unit increase) 3 : 16 8.6 (7.3) 6.2 (5.2) 1.06 (1.007, 1.12) 0.03 
OI (per 10-unit increase) 54 : 22 3.6 (2.1) 5.4 (3.4) 0.78 (0.65, 0.93) 0.006 
Intubation time* 0 : 4 66 (40.5, 111.5)* 36 (20, 64)* 2.20 (1.40, 3.45) 0.001 
Inhaled Nitric Oxide use  44 (78.6) 109 (75.7) 1.18 (0.56, 2.48) 0.67 
Inotrope Use  43 (76.8) 132 (91.7) 0.30 (0.13, 0.71) 0.006 
Pre-ECMO arrest  6 (10.7) 29 (20.1) 0.48 (0.19, 1.22) 0.12 
VA ECMO 
VV ECMO 
VV-VA ECMO 
 
3 : 3 
45 (84.9) 
6 (11.3) 
2 (3.8) 
115 (81.6) 
8 (5.7) 
18 (12.8) 
 
1.92 (0.63, 5.83)a 
0.28 (0.06, 1.27)b 
 
0.25 
0.10 
Co-Infection pre ECMO  17 (30.4) 27 (18.8) 1.89 (0.93, 3.83) 0.08 
      
On-ECMO Parameter    OR (95% CI) P value 
Co-Infection on ECMO  8 (14.3) 44 (30.6) 0.38 (0.17, 0.87) 0.02 
Renal Complication  38 (67.9) 115 (79.9) 0.53 (0.27, 1.06) 0.08 
Neurologic Complication  17 (30.4) 62 (43.1) 0.58 (0.30, 1.11) 0.10 
Any Complication 
(Renal, Neurologic, Infectious) 
 40 (71.4) 130 (90.3) 0.27 (0.12, 0.60) 0.001 
 SD: standard deviation, OR: Odds Ratio, CI: confidence interval 
*Log transformation used, median and interquartile range presented 
a VV vs VA EMCO, b VV-VA vs VA ECMO  
Table 2
Table 3: Multivariable regression analysis identifying factors independently 
associated with survival 
 
Multiple Model I (both Pre-ECMO and On-ECMO variables)    
Variable OR 95% CI P value 
Pre-ECMO Age (months) 1.43 1.03, 1.98 0.034 
Pre-ECMO P/F ratio (per 10 unit increase) 1.10 1.03, 1.17 0.003 
Pre-ECMO Intubation time* 2.10 1.37, 3.22 0.001 
Pre-ECMO Inotrope use 0.33 0.11, 0.99 0.047 
Any complication on ECMO 
(Infection, renal or neurologic) 
0.21 0.08, 0.56 0.002 
    
Multiple Model II (only Pre-ECMO variables)    
Variable OR 95% CI P value 
Pre-ECMO Age (months) 1.47 1.07, 2.04 0.019 
Pre-ECMO P/F ratio (per 10 unit increase) 1.09 1.02, 1.16 0.005 
Pre-ECMO Intubation time* 2.11 1.38, 3.23 0.001 
Pre-ECMO Inotrope use 0.31 0.11, 0.88 0.028 
* Log transformation used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Table 3
 
Table 4: Univariate and Multivariate Analysis: Expanded Pertussis Dataset (n=73) 
 
Pre-ECMO parameter Mean (SD) or number (%) 
for survivors 
n=23 
Mean (SD) or number (%) 
for non-survivors 
n=50 
Odds Ratio (95% CI) P value 
Univariate Analysis     
Highest WBC count (per 10,000) 7.8 (3.5) 7.7 (2.6) 1.01 (0.85, 1.20) 0.88 
Pulmonary Hypertension  18 (78.3) 49 (98.0) 0.07 (0.01,0.67) 0.02 
Leukodepletion received  9 (39.1) 9 (18.0) 2.93 (0.97, 8.84) 0.06 
     
Multivariate Analysis     
Pulmonary Hypertension  18 (78.3) 49 (98.0) 0.06 (0.01, 0.55) 0.01 
Leukodepletion received  9 (39.1) 9 (18.0) 3.36 (1.13, 11.68) 0.03 
SD: standard deviation, CI: confidence interval, WBC: white blood cell count 
Table 4
Figure 1 Click here to download Figure Figure 1 ROC Curve .tif 
Figure 2 Click here to download Figure Figure 2 ECMO Duration .tif 
